Don't see a position that fits? Tell us more.

We are advancing AI to power the future of medicine.

At Unlearn, our purpose is to advance artificial intelligence (AI) to eliminate trial and error in medicine. We are innovating advanced machine learning methods to leverage generative AI in forecasting patient outcomes, starting with the domain of clinical trials. We produce AI-generated digital twins of individual trial participants, enabling smaller and more efficient clinical trials to bring effective 
medicines to patients sooner.

Our innovative work in AI today will reinvent how AI is applied in medicine tomorrow — and we have a top secret plan for how to get there. We won’t be able to achieve this mission just by applying technologies created by others; the future must be invented.

Unlearn is a technology company, not a biotech company. We use computers, not pipettes. We make and use software, we don’t discover or make drugs. We believe that AI will define the future of medicine, and we aren’t deterred by naysayers or skeptics. 

We come from a variety of backgrounds ranging from machine learning to marketing—but regardless of where we come from, Unlearners share some common traits:

>> Unlearners are ambitious; we aren’t intimidated by big, challenging goals. 
>> Unlearners are disciplined experimenters; we break down our big goals into smaller chunks and meet as often as necessary to track our velocity and iterate quickly. 
>> Unlearners are gritty; we never give up, setbacks just make us try harder.
>> Unlearners are receptive to new ideas; in fact, we hate being stuck with the status quo. 
>> Unlearners are storytellers; sharing information with each other and with the world is super important, too important to be boring.  And, last but not least,
>> Unlearners are team-oriented; we put the mission first, the company second, the team third, and individuals last.

Founded in 2017 by a team of world-class machine learning scientists, we have raised venture capital from top tier investors such as Insight Partners, Radical Ventures, 8VC, DCVC, and DCVC Bio. We completed our $50 million Series B in April 2022. We are headquartered in San Francisco, CA and have an additional office in Boston, MA.

If our purpose and culture resonate with you, we invite you to apply.


Job Summary:

Don’t see a specific job that matches your qualifications? While all of our active openings are listed, feel free to apply here and detail the type of job you are looking for.
 
Please include your resume and a short write-up that explains why your skillset and experience would be an asset to Unlearn. We'll be opening several new roles soon and searching for great talent. You're encouraged to apply even if your experience doesn't precisely match the job description. We’re expecting your skills and passion to stand out—and set you apart—especially if your career has taken some extraordinary twists and turns. Please join us!
Benefits & Perks

We offer a suite of benefits and perks for our team members, including:

• Company-paid medical, dental, & vision insurance
• 401k plan with company matching
• Professional development budget for relevant conferences or workshops
• Equity education and tax advisory services
• Commuter benefits to help you get to our offices easily
• Home-office set up allowance of up to $800 for all new hires
• Flexible time off and an annual winter break (December 24 - January 1)
• Paid Parental Leave

Unlearn is an equal opportunity employer. 

At Unlearn, we are committed to building a diverse and inclusive workplace, because inclusion and diversity are essential to achieving our mission. If you’re excited about this role, and your past experience doesn’t align perfectly with every qualification in the job description, we encourage you to apply nevertheless.
Apply for this job
logo Unlearn Not provided Full-Time Hybrid 📍 San Francisco, CA or Boston, MA Apply Now
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Newsletter

Subscribe and stay updated.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Join our newsletter